Compare VSTS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VSTS | PGEN |
|---|---|---|
| Founded | 1936 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2023 | 2013 |
| Metric | VSTS | PGEN |
|---|---|---|
| Price | $12.88 | $4.20 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.88 | ★ $8.33 |
| AVG Volume (30 Days) | 2.0M | ★ 3.6M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,734,839,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $1.67 | $81.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.98 | $1.28 |
| 52 Week High | $12.93 | $5.47 |
| Indicator | VSTS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 70.40 | 50.25 |
| Support Level | $6.81 | $3.96 |
| Resistance Level | N/A | $4.40 |
| Average True Range (ATR) | 0.72 | 0.27 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 95.80 | 29.89 |
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.